Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 2/20 | 0.44 |
| ▸ | LTB4R | Q15722 | 12/20 | 0.41 |
| ▸ | LTB4R2 | Q9NPC1 | 7/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10165122 | 0.95 | DHFR (0.43) | DHFRLTB4RLTB4R2CYP4F2CYP4A11 | |
| SCHEMBL1689687 | 0.94 | DHFR (0.47) | DHFRLTB4RLTB4R2CYP4F2CYP4A11 | |
| SCHEMBL10165129 | 0.89 | LTB4R (0.41) | DHFRLTB4RLTB4R2CYP4F2CYP4A11 | |
| SCHEMBL1689993 | 0.82 | LTB4R (0.46) | DHFRLTB4RLTB4R2CYP4F2CYP4A11 | |
| SCHEMBL10165127 | 0.82 | CYP4F2 (0.49) | DHFRLTB4RLTB4R2CYP4F2CYP4A11 | |
| SCHEMBL10165121 | 0.81 | LTB4R (0.48) | LTB4RLTB4R2CYP2C9 | |
| SCHEMBL10165131 | 0.81 | CYP4F2 (0.48) | DHFRLTB4RLTB4R2CYP4F2CYP4A11 | |
| SCHEMBL10165130 | 0.76 | LTB4R (0.52) | LTB4RLTB4R2CYP2C9 | |
| SCHEMBL200784 | 0.75 | LTB4R (0.55) | DHFRLTB4RLTB4R2CYP4F2CYP4A11 | |
| SCHEMBL200601 | 0.75 | LTB4R (0.55) | DHFRLTB4RLTB4R2CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093385-B2 | Leukotriene B4 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093385-B2 | Leukotriene B4 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-01-10 | — | — | US | disclosed |
| WO-2009024492-A1 | LEUKOTRIENE B4 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-26 | — | — | WO | disclosed |
| US-20090054466-A1 | Leukotriene B4 Inhibitors | DOMINIQUE ROMYR | 2009-02-26 | — | — | US | disclosed |
| US-20090054466-A1 | Leukotriene B4 Inhibitors | DOMINIQUE ROMYR | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054466-A1 | Leukotriene B4 Inhibitors | LTB4R2, LTB4R, LTC4S | DHFR 744/4885LTB4R 2/4885LTB4R2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.